Yew Bio-Pharm Group, Inc. - FORM 10-Q

Attached files

file	filename
EX-31.1 - CERTIFICATION - Yew Bio-Pharm Group, Inc.	f10q0317ex31i_yewbiopharm.htm
EX-32 - CERTIFICATION - Yew Bio-Pharm Group, Inc.	f10q0317ex32_yewbiopharm.htm
EX-31.2 - CERTIFICATION - Yew Bio-Pharm Group, Inc.	f10q0317ex31ii_yewbiopharm.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER 000-54701

YEW BIO-PHARM GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada		26-1579105
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

9460 Telstar Avenue, Suite 6

El Monte, California 91731

(Address of principal executive offices) (Zip Code)

(626) 401-9588

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging Growth Company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 15, 2017, there were 51,875,000 shares, $0.001 par value per share, of the registrant’s common stock outstanding.

YEW BIO-PHARM GROUP, INC.

FORM 10-Q

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2015

TABLE OF CONTENTS

		Page Number

	PART I. FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS	1

	CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2017 (UNAUDITED) AND DECEMBER 31, 2016	1

	CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2017 AND 2016	2

	CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2017 AND 2016	3

	NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS	4

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	29

ITEM 4.	CONTROLS AND PROCEDURES	29

	PART II. OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	30

ITEM 1A.	RISK FACTORS	30

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	30

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	30

ITEM 4.	MINE SAFETY DISCLOSURES	30

ITEM 5.	OTHER INFORMATION	30

ITEM 6.	EXHIBITS	30

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements”, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

	●	risks related to our ability to collect amounts owed to us by some of our largest customers;
	●	our ability to continue to purchase yew cuttings from our various suppliers at relatively stable prices;
	●	our dependence on a small number of customers for our yew raw materials, including a related party ;
	●	our dependence on a small number of customers for our yew trees for reforestation;
	●	our ability to market successfully yew raw materials used in the manufacture of traditional Chinese medicine (“TCM”);
	●	industry-wide market factors and regulatory and other developments affecting our operations;
	●	our ability to sustain revenues should the Chinese economy slow from its current rate of growth;
	●	continued preferential tax treatment for the sale of yew trees and potted yew trees;
	●	uncertainties about involvement of the Chinese government in business in the People’s Republic of China (the “PRC” or “China”) generally; and
	●	any change in the rate of exchange of the Chinese Renminbi (“RMB”) to the U.S. dollar, which could affect currency translations of our results of operations, which are earned in RMB but reported in dollars;
	●	industry-wide market factors and regulatory and other developments affecting our operations;
	●	any impairment of any of our assets;
	●	a slowdown in the Chinese economy; and
	●	risks related to changes in accounting interpretations.

For a detailed description of these and other factors that could cause actual results to differ materially from those expressed in any forward-looking statement, please see the section entitled “Risk Factors”, beginning on page 15 of our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities & Exchange Commission (“SEC”) on March 31, 2017.

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2017			December 31, 2016
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	520,787		$	278,991
Accounts receivable		16,348,972			14,467,852
Accounts receivable - related party		8,075,685			6,941,931
Inventories, net		10,730,482			10,296,792
Prepaid expenses - related party		70,728			76,035
Prepaid expenses and other assets		59,897			75,743
VAT recoverables		1,251,678			1,655,954
Total Current Assets		37,058,229			33,793,298

LONG-TERM ASSETS:
Long-term inventories, net		5,305,705			7,151,613
Property and equipment, net		673,498			692,116
Land use rights and yew forest assets, net		4,562,660			4,558,234

Total Long-term Assets		10,541,863			12,401,963

Total Assets	$	47,600,092		$	46,195,261

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	944,478		$	2,700,148
Accounts payable - related parties		511,920			638,318
Accrued expenses and other payables		264,353			379,294
Notes payable		1,165,373			1,156,444
Taxes payable		4,855			16,520
Due to related parties		886,640			883,596
Short-term borrowings		4,600,922			1,723,865

Total Current Liabilities		8,378,541			7,498,185

NONCURRENT LIABILITIES:
Deferred income		121,907			120,973
Total Noncurrent Liabilities		121,907			120,973

Total Liabilities		8,500,448			7,619,158

SHAREHOLDERS’ EQUITY:
Common Stock ($0.001 par value; 140,000,000 shares authorized; 51,875,000 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively)		51,875			51,875
Additional paid-in capital		9,703,781			9,654,024
Retained earnings		27,244,528			27,074,624
Statutory reserves		3,762,288			3,762,288
Accumulated other comprehensive loss - foreign currency translation adjustment		(1,662,828	)		(1,966,708	)

Total Shareholders’ Equity		39,099,644			38,576,103

Total Liabilities and Shareholders’ Equity	$	47,600,092		$	46,195,261

See notes to these unaudited consolidated financial statements

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

	For the Three Months Ended March 31,
	2017			2016
REVENUES:
Revenues	$	5,341,203		$	576,904
Revenues - related party		2,534,261			8,043,465

Total Revenues		7,875,464			8,620,369

COST OF REVENUES:
Cost of revenues		5,301,216			627,983
Cost of revenues - related party		2,054,268			6,598,904

Total Cost of Revenues		7,355,484			7,226,887

GROSS PROFIT		519,980			1,393,482

OPERATING EXPENSES:
Selling expense		265			3,252
General and administrative expense		298,138			312,648

Total Operating Expenses		298,403			315,900

INCOME FROM OPERATIONS		221,577			1,077,582

OTHER INCOME (EXPENSES):
Interest expense		(51,963	)		(27,320	)
Other income		290			-

Total Other Expenses		(51,673	)		(27,320	)

INCOME BEFORE PROVISION FOR INCOME TAXES		169,904			1,050,262
PROVISION FOR INCOME TAXES		-			-
NET INCOME	$	169,904		$	1,050,262

COMPREHENSIVE INCOME:
NET INCOME	$	169,904		$	1,050,262
OTHER COMPREHENSIVE INCOME :
Foreign currency translation adjustment		303,880			275,422

COMPREHENSIVE INCOME	$	473,784		$	1,325,684

NET INCOME PER COMMON SHARE:
Basic	$	0.00		$	0.02
Diluted	$	0.00		$	0.02
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		51,875,000			51,875,000
Diluted		56,670,931			51,875,000

See notes to these unaudited consolidated financial statements

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended March 31,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	169,904		$	1,050,262
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation		23,220			30,504
Amortization of land use rights and yew forest assets		30,778			4,996,027
Stock-based compensation		49,757			82,598

Changes in operating assets and liabilities:
Accounts receivable		(1,770,317	)		1,980,590
Accounts receivable - related party		(1,080,518	)		(3,313,946	)
Prepaid expenses and other current assets		16,129			(788,609	)
Prepaid expenses - related party		5,896			(299,778	)
Inventories		1,542,136			(4,091,713	)
VAT recoverables		417,200			(96,129	)
Accounts payable		(1,776,755	)		46,080
Accounts payable – related parties		(131,370	)		-
Accrued expenses and other payables		(107,982	)		(16,440	)
Due to related parties		11,880			81
Taxes payable		(11,760	)		5,927

NET CASH USED IN OPERATING ACTIVITIES		(2,611,802	)		(414,546	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		-			(4,261	)

NET CASH USED IN INVESTING ACTIVITIES		-			(4,261	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term borrowings		2,880,000			-
Repayments to related parties		(20,000	)		(35,000	)
Proceeds from related parties		-			10,222

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		2,860,000			(24,778	)

EFFECT OF EXCHANGE RATE ON CASH		(6,402	)		(1,646	)

NET INCREASE (DECREASE) IN CASH		241,796			(445,231	)

CASH - Beginning of period		278,991			681,608

CASH - End of period	$	520,787		$	236,377

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for:
Interest	$	25,368		$	26,884
Income taxes	$	-		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES
Operating expense paid by related party	$	9,927		$	-

See notes to these unaudited consolidated financial statements

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated balance sheet as of December 31, 2016 was derived from the audited consolidated financial statements of Yew Bio-Pharm Group, Inc. (individually “YBP” and collectively with its subsidiaries and operating variable interest entity, the “Company”). The accompanying unaudited interim consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2016.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of March 31, 2017, and the results of operations and cash flows for the three-month periods ended March 31, 2017 and 2016, have been presented.

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company continually evaluates its estimates, including those related to bad debts, inventories, income taxes, and the valuation of equity transactions. The Company bases its estimates on historical experience and on various other assumptions that it believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

Details of the Company’s subsidiaries, variable interest entity (“VIE”) and VIE’s subsidiary are as follows:

Name	Domicile and Date of Incorporation	Registered Capital	Effective Ownership	Principal Activities
Heilongjiang Jinshangjing Bio-Technology Development Co., Limited (“JSJ”)	PRC October 29, 2009	US$100,000	100%	Holding company

Yew Bio-Pharm Holdings Limited (“Yew Bio-Pharm (HK)”)	Hong Kong November 29, 2010	HK$10,000	100%	Holding company of JSJ

Harbin Yew Science and Technology Development Co., Ltd. (“HDS”)	PRC August 22, 1996	RMB45,000,000	Contractual arrangements	Sales of yew tree components for use in pharmaceutical industry; sales of yew tree seedlings; the manufacture of yew tree wood handicrafts; and the sales of candle, pine needle extract and yew essential oil soap

Harbin Yew Food Co., Ltd (“HYF”)	PRC November 4, 2014	RMB100,000	100%(1)	Sales of wood ear mushroom drink

MC Commerce Holding Inc.(“MC”)	State of California, United State June 8, 2016		100%(2)	Sales of yew products

(1)	Wholly-owned subsidiary of HDS
(2)	51% owned by YBP and 49% owned by HDS

NOTE 2 - PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the financial statements of YBP, its subsidiaries, operating VIE in which the Company is the primary beneficiary, and VIE’s subsidiary. All significant intercompany balances and transactions have been eliminated on consolidation.

Pursuant to a restructuring plan intended to ensure compliance with applicable PRC laws and regulations (the “Second Restructure”), on November 5, 2010, JSJ entered into a series of contractual arrangements (the “Contractual Arrangements”) with HDS and/or Zhiguo Wang, his wife Guifang Qi and Xingming Han (collectively with Mr. Wang and Madame Qi, the “HDS Shareholders”), as described below:

●	Exclusive Business Cooperation Agreement. Pursuant to the Exclusive Business Cooperation Agreement between JSJ and HDS (the “Business Cooperation Agreement”), JSJ has the exclusive right to provide to HDS general business operation services, including advice and strategic planning, as well as consulting services related to technology, research and development, human resources, marketing and other services deemed necessary (collectively, the “Services”). Under the Business Cooperation Agreement, JSJ has exclusive and proprietary rights and interests in all rights, ownership, interests and intellectual properties arising out of or created during the performance of the Business Cooperation Agreement, including but not limited to copyrights, patents, patent applications, software and trade secrets. HDS shall pay to JSJ a monthly consulting service fee (the “Service Fee”) in RMB that is equal to 100% of the monthly net income of HDS. Upon the prior written consent by JSJ, the rate of Service Fee may be adjusted pursuant to the operational needs of HDS. Within 30 days after the end of each month, HDS shall (a) deliver to JSJ the management accounts and operating statistics of HDS for such month, including the net income of HDS during such month (the “Monthly Net Income”), and (b) pay 80% of such Monthly Net Income to JSJ (each such payment, a “Monthly Payment”). Within ninety (90) days after the end of each fiscal year, HDS shall (a) deliver to JSJ financial statements of HDS for such fiscal year, which shall be audited and certified by an independent certified public accountant approved by JSJ, and (b) pay an amount to JSJ equal to the shortfall, if any, of the aggregate net income of HDS for such fiscal year, as shown in such audited financial statements, as compared to the aggregate amount of the Monthly Payments paid by HDS to JSJ in such fiscal year. HDS also granted an irrevocable and exclusive option to JSJ to purchase any and all of the assets of HDS, to the extent permitted under PRC law, at the lowest price permitted by PRC law. Unless earlier terminated in accordance with the provisions of the Business Cooperation Agreement or other agreements separately executed between JSJ and HDS, the Business Cooperation Agreement is for a term of ten years and expires on November 5, 2020; however, the term of the Business Cooperation Agreement may be extended if confirmed in writing by JSJ prior to the expiration of the term thereof. The period of the extended term shall be determined exclusively by JSJ and HDS shall accept such extended term unconditionally. Unless JSJ commits gross negligence, or a fraudulent act, against HDS, HDS shall not terminate the Business Cooperation Agreement prior to the expiration of the term, including any extended term. Notwithstanding the foregoing, JSJ shall have the right to terminate the Business Cooperation Agreement at any time upon giving 30 days’ prior written notice to HDS.

●	Exclusive Option Agreement. Under an Exclusive Option Agreement among JSJ, HDS and each HDS Shareholder (individually, an “Option Agreement”), the terms of which are substantively identical to each other, each HDS Shareholder has granted JSJ or its designee the irrevocable and exclusive right to purchase, to the extent permitted under PRC law, all or any part of the HDS Shareholder’s equity interests in HDS (the “Equity Interest Purchase Option”) for RMB10. If an appraisal is required by PRC laws at the time when and if JSJ exercises the Equity Interest Purchase Option, the parties shall negotiate in good faith and, based upon the appraisal, make a necessary adjustment to the purchase price so that it complies with any and all then applicable PRC laws. Without the consent of JSJ, the HDS Shareholders shall not sell, transfer, mortgage or dispose of their respective shares of HDS stock. Additionally, without the prior consent of JSJ, the HDS Shareholders shall not in any manner supplement, change or amend the articles of association and bylaws of HDS, increase or decrease its registered capital, change the structure of its registered capital in any other manner, or engage in any transactions that could materially affect HDS’ assets, liabilities, rights or operations, including, without limitation, the incurrence or assumption of any indebtedness except incurred in the ordinary course of business, execute any major contract over RMB500,000, sell or purchase any assets or rights, incur of any encumbrance on any of its assets or intellectual property rights in favor of a third party or transfer of any agreements relating to its business operation to any third party. The term of each Option Agreement is ten years commencing on November 5, 2020 and may be extended at the sole election of JSJ.

●

Equity Interest Pledge Agreement. In order to guarantee HDS’s performance of its obligations under the Business Cooperation Agreement, each HDS Shareholder, JSJ and HDS entered into an Equity Interest Pledge Agreement (individually, a “Pledge Agreement”), the terms of which are substantially similar to each other. Pursuant to the Pledge Agreement, each HDS Shareholder pledged all of his or her equity interest in HDS to JSJ. If HDS or the HDS Shareholders breach their respective contractual obligations and such breach is not remedied to the satisfaction of JSJ within 20 days after the giving of notice of breach, JSJ, as pledgee, will be entitled to exercise certain rights, including the right to foreclose upon and sell the pledged equity interests. During the term of the Pledge Agreement, the HDS Shareholder shall not transfer his or her equity interest in HDS or place or otherwise permit any other security interest of other encumbrance to be placed on such equity interest. Upon the full payment of the Service Fee under the Business Cooperation Agreement and upon the termination of HDS’s obligations thereunder, the Pledge Agreement shall be terminated.

●

Power of Attorney. Under the Power of Attorney executed by each HDS Shareholder (each, a “Power of Attorney”), the terms of which are substantially similar to each other, JSJ has been granted an exclusive, irrevocable power of attorney to take actions in the place and stead of the HDS Shareholders, to act on behalf of the HDS Shareholder as his or her exclusive agent and attorney with respect to all matters concerning the HDS Shareholder’s equity interests in HDS, including without limitation, the right to: 1) attend shareholders’ meetings of HDS; 2) exercise all the HDS Shareholders’ rights, including voting rights under PRC laws and HDS’s Articles of Association, including but not limited to the sale or transfer or pledge or disposition of the HDS Shareholder’s equity interests in HDS in whole or in part; and 3) designate and appoint on behalf of the HDS Shareholders the legal representative, executive director, supervisor, manager and other senior management of HDS.

To the extent that the Contractual Arrangements are enforceable under PRC law, as from time to time interpreted by relevant state agencies, they constitute the valid and binding obligations of each of the parties to each such agreement.

On November 29, 2010, YBP established a wholly-owned subsidiary, Yew Bio-Pharm Holdings Limited (“Yew Bio-Pharm (HK)”), a limited liability company incorporated under the laws of Hong Kong and on January 26, 2011, YBP transferred its ownership in JSJ to Yew Bio-Pharm (HK).

The Company believes that HDS is considered a VIE under ASC 810 “Consolidation”, because the equity investors in HDS no longer have the characteristics of a controlling financial interest, and the Company, through JSJ, is the primary beneficiary of HDS and controls HDS’s operations. Accordingly, HDS has been consolidated as a deemed subsidiary into YBP as a reporting company under ASC 810.

As required by ASC 810-10, the Company performs a qualitative assessment to determine whether the Company is the primary beneficiary of HDS which is identified as a VIE of the Company. A quality assessment begins with an understanding of the nature of the risks in the entity as well as the nature of the entity’s activities including terms of the contracts entered into by the entity, ownership interests issued by the entity and the parties involved in the design of the entity. The Company’s assessment on the involvement with HDS reveals that the Company has the absolute power to direct the most significant activities that impact the economic performance of HDS. JSJ is obligated to absorb a majority of the risk of loss from HDS activities and entitles JSJ to receive a majority of HDS’s expected residual returns. In addition, HDS’s shareholders have pledged their equity interest in HDS to JSJ, irrevocably granted JSJ an exclusive option to purchase, to the extent permitted under PRC Law, all or part of the equity interests in HDS and agreed to entrust all the rights to exercise their voting power to the person(s) appointed by JSJ. Under the accounting guidance, the Company is deemed to be the primary beneficiary of HDS and the results of HDS are consolidated in the Company’s consolidated financial statements for financial reporting purposes. Accordingly, as a VIE, HDS’s sales are included in the Company’s total sales, its income from operations is consolidated with the Company’s and the Company’s net income includes all of HDS’s net income. The Company does not have any non-controlling interest and, accordingly, did not subtract any net income in calculating the net income attributable to the Company. Because of the Contractual Arrangements, YBP has a pecuniary interest in HDS that requires consolidation of HDS’s financial statements with those of the Company.

Additionally, pursuant to ASC 805, as YBP and HDS are under the common control of the HDS Shareholders, the Second Restructure was accounted for in a manner similar to a pooling of interests. As a result, the Company’s historical amounts in the accompanying consolidated financial statements give retrospective effect to the Second Restructure, whereby the assets and liabilities of the Company are reflected at the historical carrying values and their operations are presented as if they were consolidated for all periods presented, with the results of the Company being consolidated from the date of the Second Transfer Agreement. The accounts of HDS are consolidated in the accompanying financial statements.

As of March 31, 2017, the Company agreed to waive all management fees to be payable by HDS and the Company expects to waive such management fees in the near future due to a need of working capital in HDS to expand HDS’s operations.

On November 4, 2014, HDS established a new subsidiary, Harbin Yew Food Co. Ltd. (HYF), to develop and cultivate wood ear mushroom. The Company plans to operate three production lines, including wood ear mushroom polysaccharide, powder, tea and other packaged wood ear mushroom products. The move marks the Company’s entrance into the organic food and functional beverage market. HYF had limited operation activities for the three-month period ended March 31, 2017 and 2016.

On June 8, 2016, YBP established a new subsidiary, MC Commerce Holding Inc. (“MC”), in the State of California to sell the Company’s yew products in American market. During the first quarter of 2017, HDS invested in MC in the amount of $126,000. After the investment, YBP has 51% ownership interest in MC and HDS has 49% ownership interest in MC. MC has limited operation activities for the three-month period ended March 31, 2017.

The Company is principally engaged in (1) processing and selling yew raw materials used in the manufacture of traditional Chinese medicine (“TCM”); (2) growing and selling yew tree seedlings and mature trees, including potted miniature yew trees; (3) manufacturing and selling furniture and handicrafts made of yew tree timber; and (4) selling agricultural products (wood ear mushroom related) and export products (Yew candles, pine needle extracts and yew essential oil soap). The Company’s operating VIE and its subsidiary are located in Harbin, Heilongjiang Province, China.

YBP has no direct or indirect legal or equity ownership interest in HDS. However, through the Contractual Arrangements, the stockholders of HDS have assigned all their rights as stockholders, including voting rights and disposition rights of their equity interests in HDS to JSJ, our indirect, wholly-owned subsidiary. YBP is deemed to be the primary beneficiary of HDS and the financial statements of HDS are consolidated in the Company’s consolidated financial statements. At March 31, 2017 and December 31, 2016, the carrying amount and classification of the assets and liabilities in the Company’s balance sheets that relate to the Company’s variable interest in the VIE was as follows:

	March 31, 2017		December 31, 2016
Assets
Cash	$	488,703	$	249,868
Accounts receivable		16,308,721		14,427,767
Accounts receivable - related party		8,075,685		6,941,931
Inventories (current and long-term), net		15,006,062		16,746,205
Prepaid expenses and other assets		16,203		35,827
Prepaid expenses - related party		70,728		76,035
Property and equipment, net		585,262		595,338
Land use rights and yew forest assets, net		4,562,660		4,558,233
VAT recoverables		1,251,678		1,655,954
Total assets of VIE and its subsidiary	$	46,365,702	$	45,287,158
Liabilities
Accrued expenses and other payables	$	259,419	$	375,262
Accounts payable		896,785		2,654,067
Accounts payable-related parties		511,920		638,318
Taxes payable		-		11,789
Due to VIE holding companies		240,887		560,036
Short-term borrowings		4,600,922		1,723,865
Note payable		1,165,373		1,156,444
Deferred income		121,907		120,973
Due to related parties		180,137		157,484
Total liabilities of VIE and its subsidiary	$	7,977,350	$	7,398,238

Although the structure the Company has adopted is consistent with longstanding industry practice, and is commonly adopted by comparable companies in China, the PRC government may not agree that these arrangements comply with PRC licensing, registration or other regulatory requirements, with existing policies or with requirements or policies that may be adopted in the future. There are uncertainties regarding the interpretation and application of PRC laws and regulations including those that govern the Company’s contractual arrangements, which could limit the Company’s ability to enforce these contractual arrangements. If the Company or any of its variable interest entities are found to be in violation of any existing or future PRC laws, rules or regulations, or fail to obtain or maintain any of the required permits or approvals, the relevant PRC regulatory authorities would have broad discretion to take action in dealing with such violations or failures, including levying fines, revoking business and other licenses of the Company’s variable interest entities, requiring the Company to discontinue or restrict its operations, restricting its right to collect revenue, requiring the Company to restructure its operations or taking other regulatory or enforcement actions against the Company. In addition, it is unclear what impact the PRC government actions would have on the Company and on its ability to consolidate the financial results of its variable interest entities in the consolidated financial statements, if the PRC government authorities were to find the Company’s legal structure and contractual arrangements to be in violation of PRC laws, rules and regulations. If the imposition of any of these government actions causes the Company to lose its right to direct the activities of HDS and through HDS’s equity interest in its subsidiary or the right to receive their economic benefits, the Company would no longer be able to consolidate the HDS and its subsidiary.

NOTE 3 - INVENTORIES

Inventories consisted of raw materials, work-in-progress, finished goods-handicrafts, yew candles and pine needle extracts, yew seedlings, and other trees, which consist of larix, spruce and poplar trees. The Company classifies its inventories based on its historical and anticipated levels of sales; any inventory in excess of its normal operating cycle of one year is classified as long-term on its consolidated balance sheets. As of March 31, 2017 and December 31, 2016, inventories consisted of the following:

	March 31, 2017									December 31, 2016
	Current portion			Long-term portion			Total			Current portion			Long-term portion			Total
Raw materials	$	824,744		$	2,503,481		$	3,328,225		$	795,985		$	2,484,301		$	3,280,286
Finished goods		3,338,108			619,270			3,957,378			5,245,771			556,875			5,802,646
Yew seedlings		5,818,899			2,726,702			8,545,601			3,487,879			5,930,887			9,418,766
Other trees		749,361			1,990,975			2,740,336			779,537			683,323			1,462,860
Total		10,731,112			7,840,428			18,571,540			10,309,172			9,655,386			19,964,558

Inventory write-down		(630	)		(2,534,723	)		(2,535,353	)		(12,380	)		(2,503,773	)		(2,516,153	)
Inventories, net	$	10,730,482		$	5,305,705		$	16,036,187		$	10,296,792		$	7,151,613		$	17,448,405

Also see Note 9 for inventories purchased from related parties.

NOTE 4 - TAXES

(a) Federal Income Tax and Enterprise Income Taxes

The Company, YBP, registered in the state of Nevada, and its subsidiary, MC, registered in the State of California, are subject to the United States federal income tax at a tax rate of 34%. No provision for income taxes in the U.S. has been made as YBP and MC had no U.S. taxable income as of March 31, 2017 and December 31, 2016.

The Company’s subsidiary, Yew Bio-Pharm (HK), is incorporated in Hong Kong and has no operating profit or tax liabilities during the years. Yew Bio-Pharm (HK) is subject to tax at 16.5% on the assessable profits arising in or derived from Hong Kong.

The Company’s subsidiary, JSJ, and VIE and its subsidiary, HYF and HDS, incorporated in the PRC, are subject to PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Taxes (“EIT”) is generally imposed at 25%. However, HDS has been named as a leading enterprise in the agricultural industry and awarded with a tax exemption through December 31, 2058 with an exception of sales of handicrafts, yew candle, pine needle extracts and yew essential oil soap which are not within the scope of agricultural area.

The table below summarizes the difference between the U.S. statutory federal tax rate and the Company’s effective tax rate for the three months ended March 31, 2017 and 2016:

	Three Months Ended March 31,
	2017			2016
U.S. federal income tax rate		34.00	%		34.00	%
Foreign income not recognized in the U.S.		(34.00	)%		(34.00	)%
PRC EIT rate		25.00	%		25.00	%
PRC tax exemption and reduction		(28.60	)%		(26.00	)%
Income tax difference under different tax jurisdictions		1.90	%		0.58	%
Valuation allowance		1.70	%		0.42	%
Effect tax rate		-			-

Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for income tax and financial reporting purposes. Temporary differences, which give rise to a net deferred tax asset for the Company as of March 31, 2017 and December 31, 2016, are as follows:

	March 31, 2017			December 31, 2016
Tax benefit of net operating loss carry forward	$	2,162,270		$	2,105,056
Tax benefit of inventory write-down		602,717			624,891
Valuation allowance		(2,764,987	)		(2,729,947	)
Net deferred tax assets	$	-		$	-

(b) Value Added Taxes (“VAT”)

The applicable VAT tax rate is 13% for agricultural products and 17% for handicrafts, yew candles and pine needle extracts sold in the PRC. In accordance with VAT regulations in the PRC, the Company is exempt from paying VAT on its yew raw materials and yew trees sales as an agricultural corps cultivating company. The company’s sales of yew candles and pine needle extracts and export products are under VAT tax-exempt treaty and thus are eligible for return of VAT-IN. VAT payable in the PRC is charged on an aggregated basis at the applicable rate on the full price collected for the goods sold or taxable services provided and less any deductible VAT already paid by the taxpayer on purchases of goods in the same fiscal year.

NOTE 5 - SHORT-TERM BORROWINGS AND NOTES PAYABLE

On April 23, 2015, HDS entered into a loan agreement with Harbin Rongtong Branch of Bank of Communications (“BOCOM”) in the amount of RMB10,000,000 (approximately $1,630,000), payable on April 22, 2016. HDS paid off the loan in full on April 28, 2016. On May 30, 2016, HDS entered into a loan agreement with BOCOM, pursuant to which the Company obtained a bank loan in the amount of RMB10,000,000 (approximately $1,519,000), payable on May 30, 2017. The loan carries an interest rate of 5.873% per annum and is payable quarterly. Heilongjiang Zishan Technology Co., Ltd. (“ZTC”), a related party controlled by Zhiguo Wang and his wife Madame Qi, collateralized its buildings and land use right with BOCOM to secure the loan. In addition, ZTC, Heilongjiang Yew Pharmaceutical Co., Ltd. (“Yew Pharmaceutical”), a related party of the Company, Zhiguo Wang, Madame Qi, Yicheng Wang, the son of Zhiguo Wang and Yuqi Mao, the spouse of Yicheng Wang, provided guarantees to the loan.

On November 24, 2015, the Company executed a loan in the form of factoring agreement with Shanghai Pudong Development Bank (“SPD Bank”) Harbin Branch in the principal amount of RMB 10,000,000 (approx. $1,560,000). The loan carries an interest rate of 3.969% per annum and is payable, together with the principal, on November 18, 2016. HDS paid off the loan in full on November 4, 2016. On November 10, 2016, the Company entered into a loan agreement with SPD Bank, pursuant to which the Company obtained a bank loan in the amount of RMB1,970,000 (approximately $300,000), payable on November 9, 2017. The loan carries an interest rate of 5.8725% per annum and is payable quarterly. The proceeds of the loan was used by the Company to purchase raw materials. Madam Qi has secured the loan with her personal assets. In addition, Yew Pharmaceutical, Zhiguo Wang, Yichen Wang, and Yuqi Mao, the spouse of Yichen Wang provided guarantees to the loan.

On December 22, 2016, the Company entered into a credit agreement with China Everbright Bank which agreed to provide credit line of RMB 20,000,000 (approximately $2,923,000) to the Company for the period of three years. On January 18, 2017, the Company obtained a loan in the amount of $2,880,000 under this credit agreement, which is payable on July 19, 2017. The loan carries an interest rate of 4.60% per annum and is payable monthly. The loan is secured by properties and land use rights of Yew Pharmaceutical. In addition, Zhiguo Wang, Madame Qi, Yew Pharmaceutical, and ZTC provided guarantees to the loan.

On November 26, 2015, the Company issued several commercial acceptance notes to Yew Pharmaceutical with the total principal amount of RMB3,940,000 (approximately $610,000) to pay partial of the account payable owed. The terms of the commercial acceptance notes include the same maturity date of May 26, 2016 with no interest. The commercial acceptance notes are secured by a deposit of RMB1,970,000 (approximately $300,000) from the Company. On May 26, 2016, the Company paid off the commercial acceptance notes in full.

On November 4, 2016, the company issued a commercial acceptance note to Yew Pharmaceutical with the principal amount of RMB8,030,000 (approximately $1,188,000) to pay partial of the account payable owed. The commercial acceptance note was due on November 4, 2017 with no interest, secured by Madam Qi’s personal assets and guaranteed by Madam Qi, Zhiguo Wang, Yicheng Wang, Yuqi Mao and Yew Pharmaceutical.

NOTE 6 - STOCKHOLDERS’ EQUITY

Stock option activities for the three months ended March 31, 2017 and 2016 were summarized in the following table.

	Three Months Ended March 31, 2017				Three Months Ended March 31, 2016
	Number of Stock Options		Weighted Average Exercise Price		Number of Stock Options		Weighted Average Exercise Price
Balance at beginning of period		25,325,512		0.22		26,805,512		0.22
Issued		50,000		0.25
Exercised		-		-		-		-
Forfeited		-		-		-		-
Balance at end of period		25,375,512		0.22		26,805,512		0.22
Option exercisable at end of period		24,465,012		0.22		24,735,512		0.22

On February 1, 2017, the Company’s board of directors in lieu of an established compensation committee granted options pursuant to the Corporation’s 2012 Equity Incentive Plan to their employee, Jianping Han (the “Optionees V”). Within the stock option agreement, the Optionees V was issued 50,000 shares of common stock of the Company at an exercise price of $0.25 per share. The option has a term of four years starting from February 1, 2017, the vesting commencement date, and expires on February 1, 2021. The options vest and become exercisable immediately from the initial vesting commencement date.

The following table summarizes the shares of the Company’s common stock issuable upon exercise of options outstanding at March 31, 2017:

Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Price		Number Outstanding at March 31, 2017		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable at March 31, 2017		Weighted Average Exercise Price
$	0.20-0.25		25,375,512		0.79	$	0.22		24,465,012	$	0.22

The Company’s outstanding stock options and exercisable stock options had intrinsic value in the amount of $1,462,006, based upon the Company’s closing stock price of $0.28 as of March 31, 2017. Stock option expense recognized during the three months ended March 31, 2017 amounted to $49,757.

NOTE 7 - EARNINGS PER SHARE

The following table presents a reconciliation of basic and diluted net income per share for the three months ended March 31, 2017 and 2016:

	For the Three Months Ended March 31,
	2017		2016
Net income available to common stockholders for basic and diluted net income per share of common stock	$	169,904	$	1,050,262
Weighted average common stock outstanding - basic		51,875,000		51,875,000
Effect of dilutive securities:
Non-vested restricted common stock		-		-
Stock options issued to directors/officers/employees		4,795,931		-
Weighted average common stock outstanding - diluted		56,670,931		51,875,000
Net income per common share - basic	$	0.00	$	0.02
Net income per common share - diluted	$	0.00	$	0.02

NOTE 8 - CONCENTRATIONS OF CREDIT RISK AND MAJOR CUSTOMERS

Customers

For the three months ended March 31, 2017 and 2016, customers accounting for 10% or more of the Company’s revenue were as follows:

	For the Three Months Ended March 31,
Customer	2017			2016
A (Yew Pharmaceutical, a related party)		31	%		93.31	%
B		66	%		*	%
C		*	%		*	%

* Less than 10%

The three largest customers accounted for 85.1% and 99.8% of the Company’s total outstanding accounts receivable as of March 31, 2017 and December 31, 2016, respectively, of which Yew Pharmaceutical, a related party, accounted for 33.0% and 32.4% of total outstanding accounts receivable, respectively.

Suppliers

For the three months ended March 31, 2017 and 2016, suppliers accounting for 10% or more of the Company’s purchase were as follows:

	For the Three Months Ended March 31,
Supplier	2017			2016
A (Yew Pharmaceutical, a related party)		*	%		80	%
B		26	%		* %
C		21	%		* %
D		18	%		* %
E		16	%		* %
F		15	%		* %

Accounts payable to supplier B, supplier C, Changzhi Du, a related party of the Company, supplier D, supplier E and supplier F accounted for 40.0%, 31.9%, 27.1%, 23.9% and 10.0% of the Company’s total accounts payable at March 31, 2017.

Accounts payable to supplier F, supplier G, supplier C, Changzhi Du, a related party of the Company, and supplier H accounted for 24.6%, 24.1%, 17.7% and 15.8% of the Company’s total accounts payable at December 31, 2016.

NOTE 9 - RELATED PARTY TRANSACTIONS

In addition to several of the Company’s officers and directors, the Company conducted transactions with the following related parties:

Company		Ownership
Heilongjiang Zishan Technology Co., Ltd. (“ZTC”)		51% owned by Heilongjiang Hongdoushan Ecology Forest Co., Ltd., 34% owned by Zhiguo Wang, Chairman and Chief Executive Officer, 11% owned by Guifang Qi, the wife of Mr. Wang and director of the Company, and 4% owned by third parties.
Heilongjiang Yew Pharmaceutical Co., Ltd. (“Yew Pharmaceutical”)		95% owned by Heilongjiang Hongdoushan Ecology Forest Stock Co., Ltd., and 5% owned by Madame Qi.
Shanghai Kairun Bio-Pharmaceutical Co., Ltd. (“Kairun”)		60% owned by Heilongjiang Zishan Technology Co., Ltd., 20% owned by Heilongjiang Hongdoushan Ecology Forest Stock Co., Ltd., and 20% owned by Mr. Wang.
Heilongjiang Hongdoushan Ecology Forest Co., Ltd. (“HEFS”)		63% owned by Mr. Wang, 34% owned by Madame Qi, and 3% owned by third parties.
Hongdoushan Bio-Pharmaceutical Co., Ltd. (“HBP”)		30% owned by Mr. Wang, 19% owned by Madame Qi and 51% owned by HEFS
Heilongjiang Pingshan Hongdoushan Development Co., Ltd. (“HDS Development”)		80% owned by HEFS and 20% owned by Kairun
Wuchang City Xinlin Forestry Co., Ltd. (Xinlin)		98% owned by ZTC and 2% owned by HEFS effective March 21, 2016
Changzhi Du		Legal person of Xinlin
Jinguo Wang		Management of HDS
Anyangquanfeng Bio Science Inc.		84.72% owned by Mr. Wang
Heilongjiang Yew Medicine Research Institute affiliated clinics		Zhiguo Wang is the Company’s legal person

Transactions with Yew Pharmaceutical

On January 9, 2010, the Company entered into a Cooperation and Development Agreement (the “Development Agreement”) with Yew Pharmaceutical. Pursuant to the Development Agreement, for a period of ten years expiring on January 9, 2020, the Company shall supply cultivated yew raw materials to Yew Pharmaceutical that will be used by Yew Pharmaceutical to make traditional Chinese medicines and other pharmaceutical products, at price of RMB 1,000,000 (approximately $158,000) per metric ton. In addition, the Company entered into a series of wood ear mushroom selling agreements with Yew Pharmaceuticals, pursuant to which the Company sells wood ear mushroom collected from local peasants to Yew Pharmaceuticals for manufacturing of wood ear mushroom products. Furthermore, the Company entered into a series of yew candles and pine needle extracts purchase agreements with Yew Pharmaceuticals, pursuant to which the Company purchases yew candles and pine needle extracts as finished goods and then sells to third party.

For the three months ended March 31, 2017 and 2016, total sales to Yew Pharmaceutical under the above agreement amounted to $2,534,261 and $8,043,465, respectively. At March 31, 2017 and December 31, 2016, the Company had $8,075,685 and $6,941,931 accounts receivable from Yew Pharmaceutical, respectively.

For the three months ended March 31, 2017 and 2016, the total purchase of yew candles, pine needle extracts and essential yew oil soap from Yew Pharmaceutical amounted to $73,169 and $5,385,195, respectively.

For the three months ended March 31, 2017 and 2016, HYF purchased wood ear mushroom extracts from Yew Pharmaceutical in the amount of $0 and $3,785, respectively, and had accounts payable of $47,513 and $47,149 to Yew Pharmaceutical at March 31, 2017 and December 31, 2016, respectively.

At March 31, 2017 and December 31, 2016, HYF had $37,746 and $37,457, respectively, due to Yew Pharmaceutical, which represents an unsecured loan bearing no interest and payable on demand.

Transactions with HBP

For the three months ended March 31, 2017, HBP paid off operation expense on behalf of HYF in the amount of $19,986. As of March 31, 2017 and December 31, 2016, HYF had due to HBP in the amount of $78,613 and $58,178, respectively, which was included in due to related parties in the accompanying consolidated balance sheets.

Transactions with HDS Development

During the three months ended March 31, 2016, HDS prepaid $310,334 to HDS Development for purchasing yew seedlings. On June 30, 2016, the prepayment was returned to the Company in full due to the cancellation of the purchase.

Transactions with Changzhi Du

For the three months ended March 31, 2017 and 2016, HDS purchased yew seedlings from Changzhi Du in the amount of $464,563 and $0, respectively. As of March 31, 2017 and December 31, 2016, the Company had accounts payable of $464,408 and $591,169 to Changzhi Du, respectively.

Operating Leases

On March 25, 2005, the Company entered into an Agreement for the Lease of Seedling Land with ZTC (the “ZTC Lease”). Pursuant to the ZTC Lease, the Company leased 361 mu of land from ZTC for a period of 30 years, expiring on March 24, 2035. Annual payments under the ZTC Lease are RMB 162,450 (approximately $26,000). The payment for the first five years of the ZTC Lease was due prior to December 31, 2010 and beginning in 2011, the Company is required to make full payment for the land use rights in advance for each subsequent five-year period. For the three months ended March 31, 2017 and 2016, rent expense related to the ZTC Lease amounted to $5,896 and $6,210, respectively. At March 31, 2017 and December 31, 2016, prepaid rent to ZTC amounted to $70,728 and $76,035, respectively, which was included in prepaid expenses-related party on the accompanying consolidated balance sheets.

On January 1, 2010, the Company entered into a lease for office space with Mr. Wang (the “Office Lease”). Pursuant to the Office Lease, annual payments of RMB15,000 (approximately $2,000) are due for each of the term. The term of the Office Lease is 15 years and expires on December 31, 2025. For the three months ended March 31, 2017 and 2016, rent expense related to the Office Lease amounted to $544 and $573, respectively. As of March 31, 2017 and December 31, 2016, the unpaid rent was $767 and $221, respectively, which was included in due to related parties in the accompanying consolidated balance sheets.

On July 1, 2012, the Company entered into a lease for office space with Zhiguo Wang (the “JSJ Lease”). Pursuant to the JSJ Lease, JSJ leases approximately 30 square meter of office space from Zhiguo Wang in Harbin. Rent under the JSJ Lease is RMB10,000 (approximately $1,600) annually. The term of the JSJ Lease is three years and expires on June 30, 2015. On July 1, 2015, the Company and Mr. Wang renewed the JSJ Lease. The renewed lease expires on June 30, 2018. For the three months ended March 31, 2017 and 2016, rent expense related to the JSJ Lease amounted to $363 and $382, respectively. As of March 31, 2017 and December 31, 2016, the unpaid rent was $3,991 and $3,600, respectively, which was included in due to related parties in the accompanying consolidated balance sheets.

The Company leased office space from HDS Development in the A’cheng district in Harbin (the “A’cheng Lease”) on March 20, 2002. The A’cheng Lease is for a term of 23 years and expires on March 19, 2025. Pursuant to the A’cheng Lease, lease payment shall be made as follows:

Period	Annual lease amount	Payment due date
March 2002 to February 2012	RMB 25,000	Before December 2012
March 2012 to February 2017	RMB 25,000	Before December 2017
March 2017 to March 2025	RMB 25,000	Before December 2025

For the three months ended March 31, 2017 and 2016, rent expense related to the A’cheng Lease amounted $868 and $914, respectively.

Due to Related Parties

The Company’s officers, directors and other related parties, from time to time, provided advances to the Company for working capital purpose. These advances are usually short-term in nature, non-interest bearing, unsecured and payable on demand. Due to Zhiguo Wang and other shareholders, excluding the borrowings from Madame Qi as disclosed below, amounted to $307,670 and $284,626 at March 31, 2017 and December 31, 2016, respectively.

On May 15, 2015, the Company borrowed $648,000 from Madame Qi through the issuance of a subordinated promissory note. The note bears 2% interest per annum and shall be payable on or before November 15, 2015 (“Due Date”). Interest payment shall be made with principal on Due Date. On September 28, 2015, Madame Qi and the Company agreed to extend the Due Date to January 31, 2016, with the remaining terms of the note unchanged. On January 15, 2016 and 2017, the Company and Madame Qi entered into agreements to further extend the Due Date of the note to December 31, 2016 and 2017, respectively. During the three months ended March 31, 2017 and 2016, the Company made repayments of $20,000 and $35,000 to Madame Qi, respectively. As of March 31, 2017 and December 31, 2016, the total borrowings including the interest were $578,970 and $598,970, respectively, which were included in due to related parties on the accompanying consolidated balance sheets.

Research and Development Agreement

The Company entered into a Technology Development Service Agreement dated January 1, 2010 (the “Technology Agreement”) with Kairun. The term of the Technology Agreement was two years. Under the Technology Agreement, Kairun provides the Company with testing and technologies regarding utilization of yew trees to extract taxol and develop higher concentration of taxol in the yew trees the Company grow and cultivate. For these services, the Company agreed to pay Kairun RMB200,000 (approximately $32,000) after the technologies developed by Kairun are tested and approved by the Company. The Company will retain all intellectual property rights in connection with the technologies developed by Kairun. Kairun may not provide similar services to any other party without the Company’s prior written consent. In February 2012, we entered into a supplemental agreement with Kairun, extending the term of the Technology Agreement indefinitely until project results specified in the original Technology Agreement have been achieved. Kairun is owned directly and indirectly primarily by Mr. Wang and Madame Qi. As of March 31, 2017, Kairun has not yet completed the services provided for in the Technology Agreement and, therefore, no payment was made to Kairun.

NOTE 10 - SEGMENT INFORMATION

ASC 280 requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

For the three months ended March 31, 2017 and 2016, the Company operated in four reportable business segments: (1) the TCM raw materials segment, consisting of the production and sale of yew raw materials or yew tree extracts used in the manufacture of TCM; (2) the yew tree segment, consisting of the growth and sale of yew tree seedlings and mature trees; (3) the handicrafts segment, consisting of the manufacture and sale of handicrafts and furniture made of yew timber; and (4) Others including the yew candles, pine needle extracts and yew essential oil soap segment, consisting of the sale of yew candles, pine needle extracts and yew essential oil soap. The Company’s reportable segments are strategic business units that offer different products. They are managed separately based on the fundamental differences in their operations. All of the Company’s operations except the sales of yew candles, pine needle extracts and yew essential oil soap are conducted in the PRC.

Information with respect to these reportable business segments for the three months ended March 31, 2017 and 2016 was as follows:

	For the Three Months Ended, March 31,
	2017		2016
Revenues:
TCM raw materials	$	2,534,261	$	8,043,465
Yew trees		-		1,505
Handicrafts		1,361		17,250
Others		5,339,842		558,149
	$	7,875,464	$	8,620,369
Cost of revenues:
TCM raw materials	$	2,054,267	$	6,598,904
Yew trees		-		914
Handicrafts		1,262		14,354
Others		5,299,955		612,715
	$	7,355,484	$	7,226,887
Depreciation and amortization:
TCM raw materials	$	4,368	$	80,418
Yew trees		2		504
Handicrafts		3,395		6,629
Others		18,357		8,862
	$	26,122	$	96,413
Net income (loss):
TCM raw materials	$	141,915	$	1,444,561
Yew trees		-		591
Handicrafts		67		2,896
Others		27,922		(397,786	)
	$	169,904	$	1,050,262

	March 31, 2017
	TCM raw materials		Yew trees		Handicrafts		Others		Total
Identifiable long-lived assets, net	$	4,288,584	$	490,854	$	22,244	$	434,476	$	5,236,158

	December 31, 2016
	TCM raw materials		Yew trees		Handicrafts		Others		Total
Identifiable long-lived assets, net	$	4,558,234	$	436,948	$	22,218	$	232,950	$	5,250,350

The Company does not allocate any selling, general and administrative expenses, other income/expenses to its reportable segments because these activities are managed at a corporate level. In addition, the specified amounts for interest expense and income tax expense are not included in the measure of segment profit or loss reviewed by the chief operating decision maker and these specified amounts are not regularly provided to the chief operating decision maker. Therefore, the Company has not disclosed interest expense and income tax expense for each reportable segment.

Asset information by reportable segment is not reported to or reviewed by the chief operating decision maker and, therefore, the Company has not disclosed asset information for each reportable segment. The Company’s operations are located in the PRC. All revenues are derived from customers in the PRC. All of the Company’s operating assets are located in the PRC.

NOTE 11 - COMMITMENTS AND CONTINGENCIES

Operating Lease

On February 1, 2015, the Company entered into a lease for its U.S. principal office space in California. Pursuant to the office lease, the monthly payment of $3,261 is due on the first day of each month of the first year, and $3,372 for each month of the second year. The term of the lease is for 3 years and expires on January 31, 2018. For the three months ended March 31, 2017 and 2016, rent expense related to the U.S. principal office lease amounted to $10,117 and $10,116, respectively.

See Note 9 for related party operating lease commitments.

Seedling Purchase and Sale Long-Term Cooperation Agreement

On November 25, 2010, HDS entered into a Seedling Purchase and Sale Long-Term Cooperation Agreement (the “Seedling Agreement”) with Wuchang City Xinlin Foresty Co., Ltd (“Xinlin”), pursuant to which HDS will sell yew seedlings to Xinlin at a price equal to 90% of HDS’s publicly-published wholesale prices. Xinlin has agreed to purchase from the Company 10,000 yew seedlings annually. For the three months ended March 31, 2017 and 2016, the Company didn’t make sales under the Seedling Agreement.

NOTE - 12 RECENT ACCOUNTING PRONOUNCEMENT

In January 2017, the FASB issued ASU 2017-03, “Accounting Changes and Error Corrections (Topic 250) and Investments - Equity Method and Joint Ventures (Topic 323)”. This pronouncement amends the SEC's reporting requirements for public filers in regard to new accounting pronouncements or existing pronouncements that have not yet been adopted. Companies are to provide qualitative disclosures if they have not yet implemented an accounting standards update. Companies should disclose if they are unable to estimate the impact of a specific pronouncement, and provide disclosures including a description of the effect on accounting policies that the registrant expects to apply. These provisions apply to all pronouncements that have not yet been implemented by registrants. There are additional provisions that relate to corrections to several other prior FASB pronouncements. The Company has incorporated language into other recently issued accounting pronouncement notes, where relevant for the corrections in FASB ASU 2017-03. The Company is implementing the updated SEC requirements on not yet adopted accounting pronouncements with these consolidated financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our consolidated results of operations and cash flows for the three months ended March 31, 2017 and 2016, and consolidated financial conditions as of March 31, 2017 and December 31, 2016 should be read in conjunction with our unaudited consolidated financial statements and the related notes included elsewhere in this document.

Overview

We are a major grower and seller of yew trees and manufacturer of products made from yew trees, including potted yew trees for display in homes and offices, and handicrafts. We also sell branches and leaves of yew trees for the manufacture of TCM containing taxol, which TCM has been approved in the PRC for use as a secondary treatment of certain cancers, meaning it must be administered in combination with other pharmaceutical drugs. The yew industry is highly regulated in the PRC because the Northeast yew tree is considered an endangered species. We also start to sell yew candles, pine needle extracts and dietary supplement from the third and fourth quarters of 2015 and start to sell yew essential oil soap from 2016.

For the three months ended March 31, 2017 as compared to three months ended March 31, 2016, we operated in four reportable business segments: (1) the TCM raw materials segment, consisting of the production and sale of yew raw materials or yew tree extracts used in the manufacture of TCM; (2) the yew tree segment, consisting of the growth and sale of yew tree seedlings and mature trees, including potted miniature yew trees; (3) the handicrafts segment, consisting of the manufacture and sale of handicrafts and furniture made of yew timber; and (4) the “Others” segment, consisting of the sales of yew candles, pine needle extracts, dietary supplement named “Auri Essence” and yew essential oil soap. Our reportable segments are strategic business units that offer different products. The four business segments are managed separately based on the fundamental differences in their operations. All of the Company’s operations except for the dietary supplement sales are conducted in the PRC for the three months ended March 31, 2017.

For the three months ended March 31, 2017, revenues from the sales of TCM raw materials represented approximately 31.34% of consolidated revenue (including 31.34% of consolidated revenues from a related party); sales of yew trees represented approximately 0% of consolidated revenue; sales of handicrafts represented approximately 0.02% of consolidated revenue; and the sales of others represented approximately 68.64% of consolidated revenue. For the three months ended March 31, 2016, revenues from the sales of TCM raw materials represented approximately 93.31% of consolidated revenue (including 93.31% of consolidated revenues from a related party); sales of yew trees represented approximately 0.02% of consolidated revenue; the sales of handicrafts represented approximately 0.2% of consolidated revenue, and the sales of others represented approximately 6.47% of consolidated revenue.

YBP’s revenues were mostly generated by HDS and in the PRC. The expenses (approximately $162,031 and $185,399 for the three months ended March 31, 2017 and 2016, respectively) incurred in the U.S. were primarily related to fulfilling the reporting requirements of public listed company, stock-based compensation, office daily operations and other costs. As of March 31, 2017, YBP had approximately $520,787 in cash and held the 100% equity interests in its subsidiaries Yew HK and JSJ. Yew HK itself has no business operations or assets other than holding of equity interests in JSJ. JSJ has no business operations and assets with a book value of approximately $7,200, including approximately $7,200 in cash at March 31, 2017. JSJ also holds the VIE interests in HDS through the contractual arrangements (the “Contractual Arrangements”) described in Notes to Consolidated Financial Statements. On November 4, 2014, HDS established a new subsidiary, Harbin Yew Food Co. LTD. (“HYF”), to develop and cultivate wood ear mushroom drink. As of March 31, 2017, HYF had started pilot production but there was not sales yet. In the event that we are unable to enforce the Contractual Agreements, we may not be able to exert effective control over HDS and HYF, and our ability to conduct our business may be materially and adversely affected. If the applicable PRC authorities invalidate our Contractual Agreements for any violation of PRC laws, rules and regulations, we would lose control of the VIE and its subsidiary resulting in its deconsolidation in financial reporting and severe loss in our market valuation. On June 8, 2016, YBP established a new subsidiary, MC Commerce Holding Inc. (MC), to sales the Company’s yew products in American market. MC had no operation activities for the three months ended March 31, 2017.

Critical accounting policies and estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts, allowance for obsolete inventory, and the classification of short and long-term inventory, the useful life of property and equipment and intangible assets, recovery of long-lived assets, income taxes, write-down in value of inventory, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our significant judgments and estimates used in the preparation of the financial statements.

Variable interest entities

Pursuant to ASC 810 and related subtopics related to the consolidation of variable interest entities, we are required to include in our consolidated financial statements the financial statements of VIEs. The accounting standards require a VIE to be consolidated by a company if that company is subject to a majority of the risk of loss for the VIE or is entitled to receive a majority of the VIE’s residual returns. VIEs are those entities in which we, through contractual arrangements, bear the risk of, and enjoy the rewards normally associated with ownership of the entity, and therefore we are the primary beneficiary of the entity. HDS is considered a VIE, and we are the primary beneficiary. We entered into agreements with HDS pursuant to which we shall receive 100% of HDS’s net income. In accordance with these agreements, HDS shall pay consulting fees equal to 100% of its net income to our wholly-owned subsidiary, JSJ. JSJ shall supply the technology and administrative services needed to service the HDS.

The accounts of HDS are consolidated in the accompanying financial statements. As a VIE, HDS’ sales are included in our total sales, its income from operations is consolidated with ours, and our net income includes all of HDS’ net income, and their assets and liabilities are included in our consolidated balance sheets. The VIEs do not have any non-controlling interest and, accordingly, we did not subtract any net income in calculating the net income attributable to us. Because of the contractual arrangements, we have pecuniary interest in HDS that requires consolidation of HDS’ financial statements with our financial statements.

As required by ASC 810-10, we perform a qualitative assessment to determine whether we are the primary beneficiary of HDS which is identified as a VIE of us. A quality assessment begins with an understanding of the nature of the risks in the entity as well as the nature of the entity’s activities including terms of the contracts entered into by the entity, ownership interests issued by the entity and the parties involved in the design of the entity. The significant terms of the agreements between us and HDS are discussed above in the “Corporate Structure and Recapitalization - Second Restructure” section. Our assessment on the involvement with HDS reveals that we have the absolute power to direct the most significant activities that impact the economic performance of HDS. JSJ, our wholly own subsidiary, is obligated to absorb a majority of the risk of loss from HDS activities and is entitled to receive a majority of HDS’s expected residual returns. In addition, HDS’ shareholders have pledged their equity interest in HDS to JSJ, irrevocably granted JSJ an exclusive option to purchase, to the extent permitted under PRC Law, all or part of the equity interests in HDS and agreed to entrust all the rights to exercise their voting power to the person(s) appointed by JSJ. Under the accounting guidance, we are deemed to be the primary beneficiary of HDS and the results of HDS’ operation are consolidated in our consolidated financial statements for financial reporting purposes.

Accordingly, as a VIE, HDS’ sales are included in our total sales, its income from operations is consolidated with our income from operations and our net income includes all of HDS’ net income. All the equity (net assets) and profits (losses) of HDS are attributed to us. Therefore, no non-controlling interest in HDS is presented in our consolidated financial statements. As we do not have any non-controlling interest and, accordingly, did not subtract any net income in calculating the net income attributable to us. Because of the Contractual Arrangements, YBP has a pecuniary interest in HDS that requires consolidation of HDS’ financial statements with those of ours.

Additionally, pursuant to ASC 805, as YBP and HDS are under the common control of the HDS Shareholders, the Second Restructure was accounted for in a manner similar to a pooling of interests. As a result, our historical amounts in the accompanying consolidated financial statements give retrospective effect to the Second Restructure, whereby our assets and liabilities are reflected at the historical carrying values and their operations are presented as if they were consolidated for all periods presented, with our results of operations being consolidated from the date of the Second Transfer Agreement. The accounts of HDS are consolidated in the accompanying financial statements.

Accounts receivable

Accounts receivable are presented net of an allowance for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses. We review the accounts receivable balance on a periodic basis and make general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, we consider many factors, including the age of the balance, a customer’s historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection. We recognize the probability of the collection for each customer and believe the amount of the balance as of March 31, 2017 could be collected and accordingly, based on a review of our outstanding balances, we did not record any allowance for doubtful accounts.

Inventories

Inventories consisted of raw materials, work-in-progress, finished goods-handicrafts, yew seedlings, yew candles and other trees (consisting of larix, spruce and poplar trees). We classify our inventories based on our historical and anticipated levels of sales; any inventory in excess of its normal operating cycle of one year is classified as long-term on our consolidated balance sheets. Inventories are stated at the lower of cost or market value utilizing the weighted average method. Raw materials primarily include yew timber used in the production of products such as handicrafts, furniture and other products containing yew timber. Finished goods-handicraft and yew seedlings include direct materials, direct labor and an appropriate proportion of overhead.

We estimate the amount of the excess inventories by comparing inventory on hand with the estimated sales that can be sold within our normal operating cycle of one year. Any inventory in excess of our current requirements based on historical and anticipated levels of sales is classified as long-term on our consolidated balance sheets. Our classification of long-term inventory requires us to estimate the portion of inventory that can be realized over the next 12 months.

To estimate the amount of slow-moving or obsolete inventories, we analyze movement of our products, monitor competing products and technologies and evaluate acceptance of our products. Periodically, we identify inventories that cannot be sold at all or can only be sold at deeply discounted prices. An allowance will be established if management determines that certain inventories may not be saleable. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, we will record reserves for the difference between the carrying cost and the estimated market value.

Our handicraft and yew furniture products are hand-made by traditional Chinese artisans.

In accordance with ASC 905, “Agriculture”, our costs of growing yew seedlings are accumulated until the time of harvest and are reported at the lower of cost or market.

Property and equipment

Property and equipment are carried at cost and are depreciated on a straight-line basis (after taking into account their respective estimated residual value) over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. We examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The estimated useful lives are as follows:

Building			15 years
Machinery and equipment			10 years
Office equipment			3 years
Leasehold improvement			5 years
Motor vehicles			4 years

Land use rights and yew forest assets

All land in the PRC is owned by the PRC government and cannot be sold to any individual or company. We have recorded the amounts paid to the PRC government to acquire long-term interests to utilize land and yew forests as land use rights and yew forest assets. This type of arrangement is common for the use of land in the PRC. Yew trees on land containing yew tree forests are used to supply raw materials such as branches, leaves and fruit to us that will be used to manufacture our products. We amortize these land and yew forest use rights over the term of the respective land and yew forest use right, which ranges from 45 to 50 years. The lease agreements do not have any renewal option and we have no further obligations to the lessor. We record the amortization of these land and forest use rights as part of our cost of revenues.

Revenue recognition

We generate our revenue from sales of yew seedling products, sales of yew raw materials for medical application, sales of yew handicraft products, sales of “Others” including yew candles, pine needle extracts and dietary supplement and sales of wood ear mushroom. Pursuant to the guidance of ASC 605 and ASC 360, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the purchase price is fixed or determinable and collectability is reasonably assured, and no significant obligations remain.

Income taxes

We are governed by the Income Tax Law of the PRC, Hong Kong and the United States. We account for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. We record a valuation allowance to offset deferred tax assets if based on the weight of available evidence; it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

We apply the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to our liability for income taxes. Any such adjustment could be material to our results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. Currently, we have no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

Stock-based compensation

Stock based compensation is accounted for based on the requirements of the Share-Based Payment topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Currency exchange rates

Our functional currency is the U.S. dollar, and the functional currency of our operating subsidiaries and VIE is the RMB. All of our sales are denominated in RMB. As a result, changes in the relative values of U.S. dollars and RMB affect our reported levels of revenues and profitability as the results of our operations are translated into U.S. dollars for reporting purposes. In particular, fluctuations in currency exchange rates could have a significant impact on our financial stability due to a mismatch among various foreign currency-denominated sales and costs. Fluctuations in exchange rates between the U.S. dollar and RMB affect our gross and net profit margins and could result in foreign exchange and operating losses.

Our exposure to foreign exchange risk primarily relates to currency gains or losses resulting from timing differences between signing of sales contracts and settling of these contracts. Furthermore, we translate monetary assets and liabilities denominated in other currencies into RMB, the functional currency of our operating subsidiaries. Our results of operations and cash flow are translated at average exchange rates during the period, and assets and liabilities are translated at the unified exchange rate at the end of the period. Translation adjustments resulting from this process are included in accumulated other comprehensive income in our statement of shareholders’ equity. We have not used any forward contracts, currency options or borrowings to hedge our exposure to foreign currency exchange risk. We cannot predict the impact of future exchange rate fluctuations on our results of operations and may incur net foreign currency losses in the future.

Our financial statements are expressed in U.S. dollars, which is the functional currency of our parent company. The functional currency of our operating subsidiaries and affiliates is RMB. To the extent we hold assets denominated in U.S. dollars, any appreciation of the RMB against the U.S. dollar could result in a charge in our statement of operations and a reduction in the value of our U.S. dollar denominated assets. On the other hand, a decline in the value of RMB against the U.S. dollar could reduce the U.S. dollar equivalent amounts of our financial results.

Recently enacted JOBS Act

We qualify as an “emerging growth company” under the recently enacted JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, among other things, we will not be required to:

	●	Have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

	●	Submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency”;

	●	Obtain shareholder approval of any golden parachute payments not previously approved; and

	●	Disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive’s compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1 billion; (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

Until such time, however, because the JOBS Act has only recently been enacted, we cannot predict whether investors will find our stock less attractive because of the more limited disclosure requirements that we may be entitled to follow and other exemptions on which we are relying while we are an “emerging growth company”. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

Results of Operations

The following tables set forth key components of our results of operations for the periods indicated, in dollars. The discussion following the table is based on these results:

	Three Months Ended March 31,
	2017			2016
Revenues - third parties	$	5,341,203		$	576,904
Revenues - related party		2,534,261			8,043,465
Total revenues		7,875,464			8,620,369
Cost of revenues - third parties		5,301,216			627,983
Cost of revenues - related party		2,054,268			6,598,904
Total cost of revenues		7,355,484			7,226,887
Gross profit		519,980			1,393,482
Operating expenses		298,403			315,900
Income from operations		221,577			1,077,582
Other income (expenses)		(51,673	)		(27,320	)
Income Tax		-			-
Net income		169,904			1,050,262
Other comprehensive income:
Foreign currency translation adjustment		303,880			275,422
Comprehensive income	$	473,784		$	1,325,684

Three Months Ended March 31, 2017 Compared to Three Months Ended March 31, 2016

Revenues

For the three months ended March 31, 2017, we had total revenues of $7,875,464, as compared to $8,620,369 for the three months ended March 31, 2016, a decrease of $744,905 or 8.64%. The decrease in total revenue was attributable to the decrease in revenues from TCM raw materials partially offset by the increase in the “Others” segments.

Total revenue is summarized as follows:

	Three Months Ended March 31,				Increase			Percentage
	2017		2016		(Decrease)			Change
TCM raw materials	$	2,534,261	$	8,043,465	$	(5,509,203	)		(68	)%
Yew trees		-		1,505		(1,505	)		(100	)%
Handicrafts		1,361		17,250		(15,889	)		(92	)%
Others		5,339,842		558,149		4,781,693			857	%
Total	$	7,875,464	$	8,620,369	$	(744,905	)		(8.64	)%

For the three months ended March 31, 2017 compared to March 31, 2016, the decrease in revenue of TCM raw material was mainly attributable to the decrease in demand from our related party, Yew Pharmaceutical. The decrease in revenue of yew tree was mainly attributable to the Company’s strategy adjustment to reserve more yew trees for future TCM raw materials sales. The decrease in revenue of handicrafts was mainly attributable to the decline in market demand. The increase in revenue of others was mainly attributable to the increase in demand of our new product yew essential oil soap.

Cost of Revenues

For the three months ended March 31, 2017, cost of revenues amounted to $7,355,484 as compared to $7,226,887 for the three months ended March 31, 2016, an increase of $128,597 or 1.78%. For the three months ended March 31, 2017, cost of revenues accounted for 93.40% of total revenues compared to 83.84% of total revenues for the three months ended March 31, 2016.

Cost of revenues by product categories is as follows:

	Three Months Ended March 31,				Increase			Percentage
	2017		2016		(Decrease)			Change
TCM raw materials	$	2,054,267	$	6,598,904	$	(4,544,637	)		(69	)%
Yew trees		-		914		(914	)		(100	)%
Handicrafts		1,262		14,354		(13,092	)		(91	)%
Others		5,299,955		612,715		4,687,240			765	%
Total	$	7,355,484	$	7,226,887	$	128,597			1.78	%

The increase in our cost of revenues for the three months ended March 31, 2017 as compared to the three months ended March 31, 2016 was primarily a result of the decrease in costs of revenue in TCM raw materials partially offset by the increase in “Others” segments.

The decrease in cost of revenue in TCM raw material segment was primarily attributable to the decrease in sales to our related party, Yew Pharmaceutical.

The decrease in cost of revenue in yew trees segment as compared to the three months ended March 31, 2016 was due to the decreased sales of yew trees.

The decrease in cost of revenue in handicrafts for the three months ended March 31, 2017 was due to the decrease in sales of handicrafts in the first quarter of 2017.

The “Others” segment includes the sales of yew candles, pine needle extracts and yew essential oil soaps during the first quarter of 2017. The increase in the revenue from others was mainly due to the increase in sales of export commodities to Dafurong and Tiansheng, third parties.

Gross Profit

For the three months ended March 31, 2017, gross profit was $519,980 as compared to $1,393,482 for the three months ended March 31, 2016, representing gross profit margins of 6.60% and 16.17%, respectively. Gross profit margins by categories are as follows:

	Three Months Ended March 31,
	2017			2016			Increase (Decrease)

TCM raw materials		18.94	%		17.96	%		(0.98	)%
Yew trees		-	%		39.28	%		(39.28	)%
Handicrafts		7.29	%		16.79	%		(9.50	)%
Others		0.75	%		(9.78	)%		10.53	%
Total		6.60	%		16.17	%		(9.56	)%

The decrease in our overall gross profit margin for the three month ended March 31, 2017 as compared to the three months ended March 31, 2016 were primarily attributable to the decrease in revenue from TCM raw materials, which was with higher gross margin, partially offset the increase in revenue from others, which was with lower gross margin.

The decrease in our gross margin percentage related to the sale of handicrafts for the three months ended March 31, 2017 as compared to the three months ended March 31, 2016 was primarily attributable to the fact that the Company focused on sales of export commodities and disposed the handicrafts with lower gross profit.

The increase in our gross margin percentage related to the sales of yew candle, pine needle extracts and yew essential oil soap included in the “Others” segment for the three months ended March 31, 2017 as compared to the three months ended March 31, 2016 was mainly due to the rise in unit price of export commodities.

Selling Expenses

Selling expenses consisted of the following:

	Three Months Ended March 31,
	2017		2016
Salary and related benefit	$	-	$	-
Shipping and handling		-		-
Other		265		3,252
Total	$	265	$	3,252

For the three months ended March 31, 2017, selling expense was $265 as compared to $3,252 for the three months ended March 31, 2016, a decrease of $2,987, or 91.85%.

General and Administrative Expenses

For the three months ended March 31, 2017, general and administrative expenses amounted to $298,138, as compared to $312,648 for the three months ended March 31, 2016, a decrease of $14,510, or 4.64%. The decrease was mainly due to the decrease in stock-based compensation.

Income from Operations

For the three months ended March 31, 2017, income from operations was $221,577, as compared to income from operations of $1,077,582 for the three months ended March 31, 2016, a decrease of $856,005, or 79.44%. The decrease was primarily attributable to the decrease in revenues from TCM raw materials partially offset by the increase in revenues from “Others” segments.

Other Income (Expenses)

For the three months ended March 31, 2017, total other expense was $51,673 as compared to total other expenses of $27,320 for the three months ended March 31, 2016.

Net Income

As a result of the factors described above, our net income was $169,904 or $0.00 (basic and diluted), for the three months ended March 31, 2017, as compared to net income of $1,050,262 or $0.02 (basic and diluted), for the three months ended March 31, 2016.

Foreign Currency Translation Adjustment

For the three months ended March 31, 2017, we reported an unrealized gain on foreign currency translation of $303,880, as compared to a gain of $275,422 for the three months ended March 31, 2016. The change reflects the effect of the value of the U.S. dollar in relation to the RMB. These gains and loss are non-cash items. As described elsewhere herein, the functional currency of our subsidiary, JSJ, and our VIE, HDS, is the RMB. The accompanying consolidated financial statements have been translated and presented in U.S. dollars using period end rates of exchange for assets and liabilities, and average rates of exchange for the period for net revenues, costs, and expenses. Net gains resulting from foreign exchange transactions, if any, are included in the consolidated statements of income.

Comprehensive Income

For the three months ended March 31, 2017, comprehensive income of $473,784 was derived from the sum of our net income of $169,904 with foreign currency translation gain of $303,880. For the three months ended March 31, 2016, comprehensive income of $1,325,684 was derived from the sum of our net income of $1,050,262 with foreign currency translation gain of $275,422.

Segment Information

For the three months ended March 31, 2017 as compared to the three months ended March 31, 2016, we operated in four reportable business segments: (1) the TCM raw materials segment, consisting of the production and sale of yew raw materials and yew tree extracts used in the manufacture of TCM; (2) the yew tree segment, consisting of the growth and sale of yew tree seedlings and mature trees, including potted miniature yew trees; (3) the handicrafts segment, consisting of the manufacture and sale of furniture and handicrafts made of yew timber; and (4) the “Others” segment, consisting of the sales of yew candles, pine needle extracts and yew essential oil soaps. Our reportable segments are strategic business units that offer different products. The four business segments are managed separately based on the fundamental differences in their operations. All of the Company’s operations except the sales of dietary supplement named “Auri Essence” are conducted in the PRC.

Information with respect to these reportable business segments for the three months ended March 31, 2017 and 2016 was as follows:

	For the three months ended March 31, 2017						For the three months ended March 31, 2016
	Revenues- third party		Revenues- related party		Total		Revenues- third party		Revenues- related party		Total
Revenues:
TCM raw materials	$	-	$	2,534,261	$	2,534,261	$	-	$	8,043,465	$	8,043,465
Yew trees		-		-		-		1,505		-		1,505
Handicrafts		1,361		-		1,361		17,250		-		17,250
Others		5,339,842		-		5,339,842		558,149		-		558,149
Total revenues	$	5,341,203	$	2,534,261	$	7,875,464	$	576,904	$	8,043,465	$	8,620,369

Cost of sales:
TCM raw materials	$	-	$	2,054,267	$	2,054,267	$	-	$	6,598,904	$	6,598,904
Yew trees		-		-		-		914		-		914
Handicrafts		1,262		-		1,262		14,354		-		14,354
Others		5,299,955		-		5,299,955		612,715				612,715
Total cost of revenues	$	5,301,217	$	2,054,267	$	7,355,484	$	627,983	$	6,598,904	$	7,226,887

TCM raw materials

During the three months ended March 31, 2017, we sold 14,475kg of TCM raw materials as compared to 32,875 kg of TCM raw materials during the three months ended March 31, 2016, a 55.97% decrease in sales volume primarily attributable to decrease in sales volume to our related party, Yew Pharmaceutical.

In February 2010, we began selling yew branches and leaves that are used in the production of TCM. On January 9, 2010, we entered into the Development Agreement with Yew Pharmaceutical, a related party, for the development, production and sale of yew-based TCM. Pursuant to the Development Agreement, we sell yew branches and leaves to Yew Pharmaceutical. Yew Pharmaceutical manufactures TCM at its own facilities in Harbin in accordance with the requirements of the Heilongjiang Food and Drug Administration (the “HFDA”). Yew Pharmaceutical is also responsible for producing the finished product in accordance with GMP requirements. In this regard, Yew Pharmaceutical received a GMP certificate in November 2009, and has filed all applications with, and obtained all approvals from, the HFDA.

For the three months ended March 31, 2017 and 2016, we had revenue of $2,534,261and $8,043,465, respectively, from the sale of TCM raw materials to Yew Pharmaceutical. For the three months ended March 31, 2017 and 2016, revenue from the sale of TCM raw materials to third parties amounted to $nil, respectively.

Others

During the three months ended March 31, 2017, we sold approximately 73,728 yew candles, and 11,424kg pine needle extracts in amount of $5,331,080 to third parties, as compared to the sales of approximately 7,900 yew candles and 138 bottles of “Auri Essence” in amount of $558,149 to third party for the three months ended March 31, 2016.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. At March 31, 2017 and December 31, 2016, we had cash balances of $520,787 and $278,991, respectively. These funds are primarily located in various financial institutions located in China. Our primary uses of cash have been for the purchase of yew trees, land use rights and yew forest assets. Additionally, we use cash for employee compensation and working capital.

The following table sets forth information as to the principal changes in the components of our working capital from December 31, 2016 to March 31, 2017:

					December 31, 2016 to March 31, 2017
Category	March 31, 2017		December 31, 2016		Change			Percentage change
Current assets:
Cash	$	520,787	$	278,991	$	241,796			86.67	%
Accounts receivable		16,348,972		14,467,852		1,881,120			13.00	%
Accounts receivable - related party		8,075,685		6,941,931		1,133,754			16.33	%
Inventories		10,730,482		10,296,792		433,690			4.21	%
Prepaid expenses and other assets		59,897		75,743		(15,846	)		(20.92	)%
Prepaid expenses - related parties		70,728		76,035		(5,307	)		(6.98	)%
VAT recoverables		1,251,678		1,655,954		(404,276	)		(24.41	)%
Current liabilities:
Accounts payable		944,478		2,700,148		(1,755,670	)		(65.02	)%
Accounts payable - related parties		511,920		638,318		(126,398	)		(19.80	)%
Accrued expenses and other payables		264,353		379,294		(114,941	)		(30.30	)%
Notes payable		1,165,373		1,156,444		8,929			0.77	%
Taxes payable		4,855		16,520		(11,665	)		(70.61	)%
Due to related parties		886,640		883,596		3,044			0.34	%
Short-term borrowing		4,600,922		1,723,865		2,877,057			166.90	%
Working capital:
Total current assets	$	37,058,229	$	33,793,298	$	3,264,931			9.66	%
Total current liabilities		8,378,541		7,498,185		880,356			11.74	%
Working capital	$	28,679,688		26,295,113		2,384,575			9.07	%

Our working capital increased by $2,384,575 to $28,679,688 at March 31, 2017, from working capital of $26,295,113 at December 31, 2016. This increase in working capital is primarily attributable to:

	●	an increase in accounts receivable - related party of approximately $1,133,754

	●	an increase in accounts receivable of approximately $1,881,120

	●	an increase in inventories of approximately $433,690

	●	a decrease in accounts payable of approximately $1,755,670

	partially offset by:

	●	a decrease in VAT recoverables of approximately $404,276

	●	an increase in short-term borrowings of approximately 2,880,000

For the three months ended March 31, 2017, net cash flow used in operating activities was $2,611,802, as compared to net cash flow used in operating activities of $414,546 for the three months ended March 31, 2016, a decrease of $2,197,256. Because the exchange rate conversion is different for the balance sheet and the statements of cash flows, the changes in assets and liabilities reflected on the statements of cash flows are not necessarily identical with the comparable changes reflected on the balance sheets.

For the three months ended March 31, 2017, net cash flow used in operating activities of $2,611,802 was primarily attributable to:

	●	net income of approximately $169,904 adjusted for the add-back of non-cash items, such as depreciation of approximately $23,220 and amortization of land use rights and yew forest assets of approximately $30,778, stock-based compensation of approximately $49,757; and

	●	the receipt of cash from operations from changes in operating assets and liabilities, such as an increase in accounts receivable of approximately $1,770,000, an increase in accounts receivable-related party of approximately $1,081,000 and an increase in accounts payable of approximately $1,777,000;

partially offset by:

●

the use of cash from changes in operating assets and liabilities, such as an decrease in inventories of approximately $1,542,000.

For the three months ended March 31, 2016, net cash flow used in operating activities was $414,546, as compared to net cash flow provided by operating activities of $335,980 for the three months ended March 31, 2015, a decrease of $58,566. Because the exchange rate conversion is different for the balance sheet and the statements of cash flows, the changes in assets and liabilities reflected on the statements of cash flows are not necessarily identical with the comparable changes reflected on the balance sheets.

For the three months ended March 31, 2016, net cash flow used in operating activities of $414,546 was primarily attributable to:

	●	net income of approximately $1,050,262 adjusted for the add-back of non-cash items, such as depreciation of approximately $30,000 and amortization of land use rights and yew forest assets of approximately $4,996,000, stock-based compensation of approximately $82,000; and

	●	the receipt of cash from operations from changes in operating assets and liabilities, such as an increase in accounts payable of approximately $46,000 and a decrease in accounts receivable of approximately $1,980,000;

partially offset by:

●

the use of cash from changes in operating assets and liabilities, such as an increase in accounts receivable –related parties of approximately $3,313,000 and an increase in inventories of approximately $4,092,000.

Net cash flow used in investing activities was approximately $0 for the three months ended March 31, 2017. Net cash flow used in investing activities was approximately $4,000 for the three months ended March 31, 2016. During the three months ended March 31, 2016, we have made payment in approximately $4,000 for property and equipment.

Net cash flow provided by financing activities was approximately $2,860,000 for the three months ended March 31, 2017 and consisted of proceeds of approximately $2,880,000 from short-term borrowings. Net cash flow used in financing activities was approximately $25,000 for the three months ended March 31, 2016 and consisted of proceeds of approximately $10,000 from our related parties and repayment of approximately $35,000 to our related parties.

We have historically financed our operations and capital expenditures through cash flows from operations, bank loans and advances from related parties. From March 2008 to September 2009, we received approximately $2.9 million of proceeds in the aggregate from offerings and sales of our common stock. Except for the portion used to pay for professional and other expenses in the U.S., substantial portions of the proceeds we received through sales of our common stock were retained in the PRC and used to fund our working capital requirements. As the PRC government imposes controls on PRC companies’ ability to convert RMB into foreign currencies and the remittance of currency out of China, from time to time, in order to fund our corporate activities in the U.S., Zhiguo Wang, our President and CEO, advanced funds to us in the U.S. and we repaid the amounts owed to him in RMB in the PRC.

It is management’s intention to expand our operations as quickly as reasonably practicable to capitalize on the demand opportunity for our products. We regularly review our cash funding requirements and attempt to meet those requirements through a combination of cash on hand, cash provided by operations and any potential available bank borrowings. We believe that we can continue meeting our cash funding requirements for our business in this manner over at least the next twelve months. The majority of our funds are maintained in RMB in bank accounts in China. We receive most of our revenue in the PRC. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and expenditures from trade related transactions, can be made in foreign currencies by complying with certain procedural requirements. However, approval from China’s State Administration of Foreign Exchange (“SAFE”) or its local counterparts is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may also, at its discretion, restrict access to foreign currencies for current account transactions. As of March 31, 2017 and December 31, 2016, approximately $39.1 million and $38.6 million, respectively, of our net assets are located in the PRC. If the foreign exchange control system in the PRC prevents us from obtaining sufficient foreign currency to satisfy our currency demands, we may not be able to transfer funds deposited within the PRC to fund working capital requirements in the U.S. or pay any dividends in currencies other than the RMB, to our shareholders.

Off-Balance Sheet Arrangements

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Exchange Rates Risk

Substantially all of our operating revenues and expenses are denominated in RMB. We operate using RMB and the effects of foreign currency fluctuations are largely mitigated because local expenses in the PRC are also denominated in the same currency. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Because we generally receive cash flows denominated in RMB, our exposure to foreign exchange risks should be limited.

Our assets and liabilities, of which the functional currency is the RMB, are translated into USD using the exchange rates in effect at the balance sheet date, resulting in translation adjustments that are reflected as cumulative translation adjustment in the shareholders’ equity section on our consolidated balance sheets. A portion of our net assets are impacted by changes in foreign currencies translation rates in relation to the U.S. dollar. We recorded a foreign currency translation gains of $ 303,880 and of $275,422 for the three months ended March 31, 207 and March 31, 2016, respectively, to reflect the impact of the fluctuation of the RMB against the U.S. dollar.

The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. The conversion of the RMB into foreign currencies, including U.S. dollars, has been based on rates set by the People’s Bank of China.

To the extent that we decide to convert RMB denominated cash amounts into U.S. dollars for the purpose of making any dividend payments, which we have not declared but may declare in the future, or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount available to us. Conversely, if we need to convert U.S. dollars into RMB for operations, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount it received from the conversion. We have not used, and do not currently expect to use in the future, any forward contracts or currency borrowings to hedge exposure to foreign currency exchange risk.

Interest Rate Risk

We have not been, nor do we currently anticipate being, exposed to material risks due to changes in interest rates.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures.

The Company’s management has evaluated, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this report.

(b) Changes in Internal Control over Financial Reporting.

There have not been any changes in the Company’s internal control over financial reporting that occurred during the Company’s fiscal quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any lawsuit or proceeding which, in the opinion of management, is likely to have a material adverse effect on us or our business.

ITEM 1A. RISK FACTORS

No material change.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibits are attached hereto and filed herewith:

31.1*	Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

31.2*	Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

32*	Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	XBRL Taxonomy Extension Label Linkbase Document

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

*Filed herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	YEW BIO-PHARM GROUP, INC.

	By:	/s/ ZHIGUO WANG
		Zhiguo Wang
		Chief Financial Officer

Date: May 15, 2017

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
31.1*		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

31.2*		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

32*		Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*Filed herewith.

Attached files

Yew Bio-Pharm Group, Inc. Reports

Also read